Starting from an innovative starting point with an expected output soon, a modular high-tech follow-up is already being considered. Innovative medical radioisotopes could be produced there and distributed from here at lightning speed.

With London, UK and Fukuoka, Japan as the next dedicated hubs for both basic and innovative radioisotopes.

An advanced liver endocrine factor analog with capacity to mitigate blood sugar spikes and thus potentially contributing to logevity depending on current metabolic function and health pattern of the user.

New additional +Locations in the Alcydon adventure will be both in Brussels and London. We'll also try to shape bold ideas from these extra locations whereby our courageous endeavours will now also extend to the heart of old Europe.

Alcydon initiates research into to the relevance of developing a cell and gene therapy division. The aim is to achieve excellent, accessible and affordable solutions for everyone who needs them. In complete synergy and symmetry with the Alcydon XTL product line, 8 solutions will also be addressed here; namely CGT1, CGT2, CGT3, CGT4, CGT5, CGT6, CGT7 and CGT8. The last in line will be particularly focused on possible life extension.

Open for collaboration.

This research will investigate whether, in addition to potentially improved muscle integrity and strentgh, improved overall growth can also be achieved, and whether side effects of glucocorticoïds can be mitigated.

Open for collaboration.